AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31257987 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous imputation across all subjects
Number of subjects: 0
Study 30270167 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 321
Study 30270167 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 321
Study 28213388 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine donor pretreatment (4 µg/kg per minute continuous infusion)
Number of subjects: 487
Study 28213388 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dopamine infusion)
Number of subjects: 487
Study 28213388 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine donor pretreatment with infusion time of 7.1 hours
Number of subjects: 487
Study 24951103 — intervention group
Group type: COMPARATOR
Intervention: Atacicept 75 mg
Number of subjects: 461
Study 24951103 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept 150 mg
Number of subjects: 461
Study 24951103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 461
Study 23391369 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9668 (150 mg single dose, 70 mg twice daily multiple doses)
Number of subjects: 125
Study 23391369 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9668
Number of subjects: 125
Study 22043122 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Adenotonsillectomy (eAT)
Number of subjects: 0
Study 22043122 — intervention group
Group type: COMPARATOR
Intervention: Watchful Waiting with Supportive Care (WWSC)
Number of subjects: 0
Study 19117833 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and calcium supplementation (100,000 IU bimonthly and 1 g/day calcium)
Number of subjects: 56
Study 19117833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 17674917 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 5-fluorouracil (5-FU) and low-molecular-weight heparin (LMWH) with silicone oil
Number of subjects: 64
Study 17674917 — intervention group
Group type: COMPARATOR
Intervention: Silicone oil without adjunctive medication (control group)
Number of subjects: 64
Study 17674917 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 5-FU and LMWH with silicone oil
Number of subjects: 64
Study 14724665 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg/day plus metoprolol 25 mg/day (group M)
Number of subjects: 57
Study 14724665 — intervention group
Group type: COMPARATOR
Intervention: Sibutramine 10 mg/day plus placebo (group P)
Number of subjects: 57
Study 11291370 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-delivered intervention consisting of group discussions, outreach, and educational campaigns over 16 months.
Number of subjects: 2747
Study 9278651 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin, 40 mg once daily, beginning 2 hours before surgery
Number of subjects: 631
Study 9278651 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated low-dose heparin, three times daily
Number of subjects: 631
Study 8314960 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 ng/ml EGF
Number of subjects: 262
Study 8314960 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.0 ng/ml EGF
Number of subjects: 262
Study 8314960 — intervention group
Group type: COMPARATOR
Intervention: Control (no EGF)
Number of subjects: 262
Study 3578401 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptive preparations (seven types)
Number of subjects: 10
Study 28703491 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC) plus two N(t)RTIs
Number of subjects: 238
Study 28703491 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted protease inhibitor (PI/r)
Number of subjects: 238
Study 28703491 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC)
Number of subjects: 238
Study 26261074 — intervention group
Group type: COMPARATOR
Intervention: 200 U BTX‐A intradetrusor injections excluding the trigone (Control group)
Number of subjects: 91
Study 26261074 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 U intradetrusor and 40 U intratrigonal injections (Experimental group)
Number of subjects: 91
Study 25335244 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus electric stimulation
Number of subjects: 74
Study 25335244 — intervention group
Group type: COMPARATOR
Intervention: Electric stimulation
Number of subjects: 74
Study 23439172 — intervention group
Group type: EXPERIMENTAL
Intervention: Accu-Chek SmartPix information management system (IMS)
Number of subjects: 25
Study 23439172 — intervention group
Group type: COMPARATOR
Intervention: Handwritten logbooks
Number of subjects: 25
Study 20184578 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening participants (PSA testing)
Number of subjects: 1000
Study 20184578 — intervention group
Group type: COMPARATOR
Intervention: Non-participants (no PSA testing)
Number of subjects: 1000
Study 19138485 — intervention group
Group type: EXPERIMENTAL
Intervention: Scarf osteotomy
Number of subjects: 115
Study 19138485 — intervention group
Group type: COMPARATOR
Intervention: Chevron osteotomy
Number of subjects: 115
Study 16634976 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 16634976 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of social support
Number of subjects: 0
Study 16634976 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate or large amounts of stress
Number of subjects: 0
Study 12864879 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor (ramipril)
Number of subjects: 0
Study 12864879 — intervention group
Group type: COMPARATOR
Intervention: Dihydropyridine calcium channel blocker (DHP-CCB, amlodipine)
Number of subjects: 0
Study 12864879 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker (metoprolol)
Number of subjects: 0
Study 11472003 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential mode ablation technique
Number of subjects: 58
Study 11472003 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized mode ablation technique
Number of subjects: 58
Study 11472003 — intervention group
Group type: COMPARATOR
Intervention: PMMA test plates
Number of subjects: 58
Study 9258527 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza split vaccine
Number of subjects: 124
Study 9258527 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza split vaccine + Pneumococcal 23-valent vaccine
Number of subjects: 124
Study 9258527 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal 23-valent vaccine (administered simultaneously with influenza vaccine)
Number of subjects: 124
Study 9258527 — intervention group
Group type: COMPARATOR
Intervention: Control group (Influenza vaccine alone)
Number of subjects: 124
Study 7943888 — intervention group
Group type: EXPERIMENTAL
Intervention: Film-forming preparation 'Lifusol' for catheter fixation
Number of subjects: 0
Study 7943888 — intervention group
Group type: COMPARATOR
Intervention: Standard catheter fixation with plaster
Number of subjects: 0
Study 2945783 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human atrial natriuretic peptide (i.v. bolus of 25 micrograms followed by a 6‐hour infusion of 25 micrograms/hr)
Number of subjects: 6
Study 2945783 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human atrial natriuretic peptide (i.v. bolus of 175 micrograms followed by a 6‐hour infusion of 100 micrograms/hr)
Number of subjects: 6
Study 2945783 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II (5, 10, 20 ng/kg/min)
Number of subjects: 6
Study 29415668 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 44
Study 29415668 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 44
Study 26742001 — intervention group
Group type: EXPERIMENTAL
Intervention: Live Attenuated Influenza Vaccine (LAIV), administered to 77 children, analyzed 63 children after vaccination.
Number of subjects: 151
Study 26742001 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-recipients of LAIV), 74 children, analyzed 72 children.
Number of subjects: 151
Study 24771132 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling vest
Number of subjects: 10
Study 21985488 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (800 mg/day, intravenous infusion and oral supplementation)
Number of subjects: 96
Study 21985488 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pentoxifylline)
Number of subjects: 96
Study 19671203 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsinoids (1 mg)
Number of subjects: 13
Study 19671203 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsinoids (3 mg)
Number of subjects: 13
Study 19671203 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsinoids (6 mg)
Number of subjects: 13
Study 19671203 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsinoids (12 mg)
Number of subjects: 13
Study 19671203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 19046245 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 824
Study 15838406 — intervention group
Group type: COMPARATOR
Intervention: Medical care only (MD)
Number of subjects: 681
Study 15838406 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care only (DC)
Number of subjects: 681
Study 15838406 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care with physical modalities (DCPm)
Number of subjects: 681
Study 15838406 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical care with physical therapy (MDPt)
Number of subjects: 681
Study 11461054 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-simulated point-light demonstrations
Number of subjects: 0
Study 11461054 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal video demonstrations
Number of subjects: 0
Study 11461054 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time demonstrations
Number of subjects: 0
Study 11461054 — intervention group
Group type: COMPARATOR
Intervention: Slow-motion demonstrations
Number of subjects: 0
Study 9609609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline therapy
Number of subjects: 38
Study 9609609 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline solution)
Number of subjects: 38
Study 7925877 — intervention group
Group type: EXPERIMENTAL
Intervention: Candoxatril 200 mg
Number of subjects: 10
Study 7925877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3354350 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 14
Study 3354350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1306679 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice (0.3% triclosan and 2.0% copolymer)
Number of subjects: 325
Study 1306679 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 325
Study 417428 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydergine (Sandoz)
Number of subjects: 300
Study 417428 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 300
Study 417428 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 300
Study 417428 — intervention group
Group type: COMPARATOR
Intervention: General supportive treatment
Number of subjects: 300
Study 31147306 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump (IABP) 50 mL
Number of subjects: 32
Study 31147306 — intervention group
Group type: COMPARATOR
Intervention: Inotropes (INO: enoximone or dobutamine)
Number of subjects: 32
Study 27832835 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue antenatal steroids
Number of subjects: 113
Study 27832835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 26459347 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined epidural-general anesthesia plus postoperative epidural analgesia
Number of subjects: 1800
Study 26459347 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia plus postoperative intravenous analgesia
Number of subjects: 1800
Study 24267010 — intervention group
Group type: EXPERIMENTAL
Intervention: CNV1014802
Number of subjects: 30
Study 24267010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21212157 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg BIBF 1120 b.i.d.
Number of subjects: 73
Study 21212157 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg BIBF 1120 b.i.d.
Number of subjects: 73
Study 21212157 — intervention group
Group type: EXPERIMENTAL
Intervention: BIBF 1120 (both doses)
Number of subjects: 73
Study 19364975 — intervention group
Group type: EXPERIMENTAL
Intervention: Alert from hospital staff to attending physician
Number of subjects: 2493
Study 19364975 — intervention group
Group type: COMPARATOR
Intervention: No alert issued (Control)
Number of subjects: 2493
Study 17374147 — intervention group
Group type: EXPERIMENTAL
Intervention: AKL1
Number of subjects: 32
Study 17374147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 15153206 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-breath (DB) VC inhalation induction with 8% sevoflurane in 66% nitrous oxide
Number of subjects: 104
Study 15153206 — intervention group
Group type: COMPARATOR
Intervention: Single-breath (SB) VC inhalation induction with 8% sevoflurane in 66% nitrous oxide
Number of subjects: 104
Study 11409130 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate (GS) 500 mg tid
Number of subjects: 39
Study 11409130 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg tid
Number of subjects: 39
Study 11409130 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate (GS)
Number of subjects: 39
Study 11409130 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 39
Study 9773910 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone (2 mg/kg/day) for 3 days
Number of subjects: 38
Study 9773910 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 days
Number of subjects: 38
Study 9773910 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (prednisone and placebo)
Number of subjects: 38
Study 8153771 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 500 mg
Number of subjects: 222
Study 8153771 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 250 mg
Number of subjects: 222
Study 3079005 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide (400 mg twice daily, administered intramuscularly)
Number of subjects: 63
Study 3079005 — intervention group
Group type: COMPARATOR
Intervention: Calcium heparin (5,000 IU thrice daily, administered subcutaneously)
Number of subjects: 63
Study 3079005 — intervention group
Group type: COMPARATOR
Intervention: ASA (100 mg on alternate days, administered orally)
Number of subjects: 63
Study 3079005 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide
Number of subjects: 63
Study 3079005 — intervention group
Group type: COMPARATOR
Intervention: Calcium heparin
Number of subjects: 63
Study 3079005 — intervention group
Group type: COMPARATOR
Intervention: ASA
Number of subjects: 63
Study 31899878 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan administration
Number of subjects: 60
Study 31899878 — intervention group
Group type: COMPARATOR
Intervention: No sumatriptan administration (Control)
Number of subjects: 60
Study 31166599 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 300 mg Q4W
Number of subjects: 458
Study 31166599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study 28637470 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls in Sport intervention
Number of subjects: 1769
Study 28637470 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1769
Study 25733626 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols (PS) consumption (2 g PS/d for 28 days)
Number of subjects: 63
Study 25733626 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols (PS) consumption (2 g PS/d for 28 days) in LS individuals
Number of subjects: 63
Study 25733626 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols (PS) consumption (2 g PS/d for 28 days) in HS individuals
Number of subjects: 63
Study 25733626 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols (PS) consumption (2 g PS/d for 28 days) in LS participants
Number of subjects: 63
Study 23256446 — intervention group
Group type: EXPERIMENTAL
Intervention: 12‐week honey consumption (0.5 mL/kg body weight per day)
Number of subjects: 20
Study 23256446 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term effects after honey withdrawal
Number of subjects: 20
Study 21530103 — intervention group
Group type: EXPERIMENTAL
Intervention: Swanson implants
Number of subjects: 33
Study 21530103 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuFlex implants
Number of subjects: 33
Study 21530103 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient motivations for surgery
Number of subjects: 33
Study 21530103 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient satisfaction
Number of subjects: 33
Study 21530103 — intervention group
Group type: EXPERIMENTAL
Intervention: Michigan Hand Questionnaire
Number of subjects: 33
Study 21530103 — intervention group
Group type: EXPERIMENTAL
Intervention: Sollerman hand function test
Number of subjects: 33
Study 21530103 — intervention group
Group type: EXPERIMENTAL
Intervention: Range of motion, ulnar drift, grip strength
Number of subjects: 33
Study 18316155 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban i.v.
Number of subjects: 140
Study 18316155 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine i.v.
Number of subjects: 140
Study 16493482 — intervention group
Group type: EXPERIMENTAL
Intervention: Otamixaban (0.3 mg/kg)
Number of subjects: 68
Study 16493482 — intervention group
Group type: EXPERIMENTAL
Intervention: Otamixaban (0.5 mg/kg)
Number of subjects: 68
Study 16493482 — intervention group
Group type: EXPERIMENTAL
Intervention: Otamixaban (0.3 mg/kg) with ASA (300 mg once a day)
Number of subjects: 68
Study 16493482 — intervention group
Group type: EXPERIMENTAL
Intervention: Otamixaban (0.5 mg/kg) with ASA (300 mg once a day)
Number of subjects: 68
Study 16493482 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) (300 mg once a day)
Number of subjects: 68
Study 12859127 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect word learning
Number of subjects: 96
Study 12859127 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct word learning
Number of subjects: 96
Study 11168746 — intervention group
Group type: EXPERIMENTAL
Intervention: Curette/curette
Number of subjects: 10
Study 11168746 — intervention group
Group type: EXPERIMENTAL
Intervention: Curette/teflon‐coated sonic scaler
Number of subjects: 10
Study 11168746 — intervention group
Group type: EXPERIMENTAL
Intervention: Teflon‐coated sonic scaler/teflon‐coated sonic scaler
Number of subjects: 10
Study 11168746 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 10
Study 9783766 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillamine
Number of subjects: 541
Study 9783766 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium aurothiomalate
Number of subjects: 541
Study 9783766 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 541
Study 9783766 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 541
Study 9783766 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 541
Study 7843470 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 48
Study 7843470 — intervention group
Group type: COMPARATOR
Intervention: Glipizide
Number of subjects: 48
Study 2455840 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol, 200 mg
Number of subjects: 8
Study 2455840 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol, 50 mg
Number of subjects: 8
Study 2455840 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol, 8 mg
Number of subjects: 8
Study 2455840 — intervention group
Group type: COMPARATOR
Intervention: ICI 118,551, 25 mg with Xamoterol
Number of subjects: 8
Study 2455840 — intervention group
Group type: COMPARATOR
Intervention: ICI 118,551, 25 mg with Prenalterol
Number of subjects: 8
Study 2455840 — intervention group
Group type: COMPARATOR
Intervention: ICI 118,551, 25 mg with Salbutamol
Number of subjects: 8
Study 31533552 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenomics testing using OneOme RightMed comprehensive test
Number of subjects: 155
Study 29170309 — intervention group
Group type: EXPERIMENTAL
Intervention: New prognostic model for management of blunt chest wall trauma patients
Number of subjects: 0
Study 29170309 — intervention group
Group type: COMPARATOR
Intervention: Normal care (control)
Number of subjects: 0
Study 29170309 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-12v2 and Client Services Receipt Inventory surveys
Number of subjects: 0
Study 25514106 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab, 60 mg s.c. every 6 months
Number of subjects: 1703
Study 25514106 — intervention group
Group type: COMPARATOR
Intervention: Oral bisphosphonates (ibandronate or risedronate, 150 mg once monthly for 12 months)
Number of subjects: 1703
Study 23466048 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 32
Study 23466048 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 32
Study 23466048 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 32
Study 21533723 — intervention group
Group type: EXPERIMENTAL
Intervention: frovatriptan 2.5 mg
Number of subjects: 76
Study 21533723 — intervention group
Group type: COMPARATOR
Intervention: zolmitriptan 2.5 mg
Number of subjects: 76
Study 19167726 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 941
Study 19167726 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil
Number of subjects: 941
Study 19167726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 941
Study 16730606 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent Patient-Provider Interaction Scale (APPIS)
Number of subjects: 192
Study 15259834 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram, 20 mg/day
Number of subjects: 16
Study 15259834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16